Objective To explore the clinical efficacy of fluvoxamine and fluoxetine in treatment of patients during acute phase of depression.Methods One hundred and twenty-four patients with acute phase of depression attending Psychology Department of Xuzhou Oriental People's Hospital from December 2021 to September 2023 were included,and grouped using random number ta-ble method,with 62 in each.The patients in the control group received fluoxetine(20 mg·d-1,once a day),while those in the observa-tion one fluvoxamine(50 mg·d-1,once a day).Treatment in both groups lasted for 8 weeks.Then the clinical efficacy,high-sensitivity C-reactive protein(hs-CRP)levels and the occurrence of adverse reactions were compared between the two groups.Results After treatment for 8 weeks,the HAMD-17 scores of both groups were lower than those before treatment,and the HAMD-17 score of the observation group(8.33±1.29)was lower than that of the control(11.35±1.54)after treatment,and the difference was statistically significant(P<0.05).Observation group reported higher clinical efficacy rate as compared to the control(90.32%vs 74.19%,P<0.05).A reduction was found in hs-CRP in all patients after treatment,and study group showed a lower hs-CRP level than the control((3.82±1.20)mg·L-1 vs(4.32±1.47)mg·L-1,both P<0.05).The incidence of adverse reactions in the observation group(9.68%)was lower than that in the control(17.74%),but the difference was not statistically significant when comparing the two groups(χ2=1.704,P>0.05).Conclusion Fluvoxamine is superior to fluoxetine in the treatment of patients during the acute phase of depression,which can decrease hs-CRP levels,attenuate inflammatory response,improve immune function,promote the recovery of patients and has a good safety profile.
FluvoxamineFluoxetineDepressionClinical efficacyHigh-sensitivity C-reactive protein
NETL
NSTL
万方数据
